- videocam Live Webinar with Live Q&A
- calendar_month July 16, 2026 @ 1:00 PM ET/10:00 AM PT
- signal_cellular_alt Intermediate
- card_travel Health
- schedule 90 minutes
100% Tariffs Impacting the Pharmaceutical Industry: Section 232, Complex Multi-Tiered Rate Structure, Exemptions
Welcome to BARBRI, the trusted global leader in legal education. Continue to access the same expert-led Strafford CLE and CPE webinars you know and value. Plus, explore professional skills courses and more.
About the Course
Introduction
This CLE webinar will closely examine the recent proclamation issued by the Trump administration imposing 100% tariffs on imported patented pharmaceuticals and related ingredients under Section 232 of the Trade Expansion Act of 1962 (Section 232). The panel will discuss the complex tiered rate structure and address the impact these changes will have on the pharmaceutical industry, including cost increases and potential supply chain issues. The panel will also offer best practices for compliance.
Description
The Trump administration recently issued a proclamation imposing sweeping tariffs on patented pharmaceuticals and related ingredients under Section 232, citing threats to national security and the economy as the reason.
Beginning as early as July 31, 2026 for certain large pharmaceutical companies and becoming widely effective on Sept. 29, 2026 for all covered entities, a baseline tariff of 100% will be imposed on imports of patented pharmaceuticals, biologics, and associated ingredients impacting pharmaceutical manufacturers, importers, and supply chain participants.
The proclamation establishes a complex, multi-tiered rate structure and allows for certain company, country, and product-specific tariff reductions and exemptions—all with the purpose of pushing companies toward domestic manufacturing and pricing concessions.
Counsel with clients in the pharmaceutical and life sciences industries should have a clear understanding of the new tariff structure and how it will impact their clients, including cost increases, supply chain disruptions, and changes in business practices.
Listen as our expert panel closely examines the recent proclamation and the new tariff structure. The panel will address the impact these changes will have on the pharmaceutical industry and discuss next steps that counsel and clients should be taking now.
Presented By
For more than four decades, Mr. Bass has advised companies and governments on compliance, regulatory, and commercialization issues across the United States, Europe, and Asia, advising a majority of the top pharmaceutical, medical device, and dietary supplement manufacturers, distributors, and Contract Research Organizations in bet-the-company regulatory, enforcement, and commercialization matters. He is recognized for his strategic guidance at the intersection of innovation, compliance, and enforcement—particularly where regulatory risk meets business-critical deals. Mr. Bass has led the defense of high-stakes criminal and civil investigations, managed complex audits, and brings the benefit of formal mediator training to resolve entrenched disputes with efficiency. Mr. Bass is considered the foremost authority on U.S dietary supplement law. One of the principal drafters of the Dietary Supplement Health and Education Act, he has authored three books on the subject and is co-author of a recent New England Journal of Medicine article on necessary changes to that law. He has served as counsel to many of the top associations in this field, including the global OTC drug federation.
Ms. Gustafson focuses her practice on U.S. customs and international trade matters. She advises multinational clients in a wide range of customs and trade areas including customs valuation, classification, country of origin, preferential trade programs, mergers and acquisitions due diligence, import compliance, reconciliation, duty mitigation, compliance reviews, and disclosures. Prior to joining the firm, Ms. Gustafson served as a customs and international trade consultant for multinational professional services organizations. She brings extensive experience in leading valuation planning and duty mitigation strategies, preparing and submitting binding ruling requests to CBP, as well as representing clients in CBP audits and inquiries. Ms. Gustafson received her Customs broker license in 2021.
Ms. McNulty advises U.S. and international clients on a range of complex international trade issues, dynamic U.S. and global tariff matters, and related trade compliance questions, including tariff stacking. She provides legal, policy, and strategic advice to companies, trade associations, and governments on international economic policy matters, and assists clients in navigating geopolitical risk. She advises clients on the negotiation and enforcement of international trade agreements, including enforcement proceedings arising under the facility-specific rapid response labor mechanism of the USMCA. Ms. McNulty regularly represents clients before U.S. agencies such as the Office of the U.S. Trade Representative (USTR) and the U.S. Department of Commerce, including in proceedings arising under Section 301 of the Trade Act of 1974 and Section 232 of the Trade Expansion Act of 1962. She also litigates before the U.S. Court of International Trade and represents clients in antidumping and countervailing duty (AD/CVD) proceedings.
-
This 90-minute webinar is eligible in most states for 1.5 CLE credits.
-
Live Online
On Demand
Date + Time
- event
Thursday, July 16, 2026
- schedule
1:00 PM ET/10:00 AM PT
I. Introduction
A. Presidential authority under Section 232
II. The proclamation
A. Purpose
B. Covered entities
C. Key definitions
D. Tiered rate structure
E. Exemptions
III. Next steps for counsel and clients
A. Risk assessment
B. Supply chain review
C. Other
IV. Key takeaways
The panel will review these and other important issues:
- Under what authority are the new tariffs imposed?
- What is the purpose behind the proclamation?
- How will the complex multi-tiered rate structure impact covered entities in the pharmaceutical industry?
- What should counsel and their covered clients be doing to prepare for compliance?
Unlimited access to premium CLE courses:
- Annual access
- Available live and on-demand
- Best for attorneys and legal professionals
Unlimited access to premium CPE courses.:
- Annual access
- Available live and on-demand
- Best for CPAs and tax professionals
Unlimited access to premium CLE, CPE, Professional Skills and Practice-Ready courses.:
- Annual access
- Available live and on-demand
- Best for legal, accounting, and tax professionals
Unlimited access to Professional Skills and Practice-Ready courses:
- Annual access
- Available on-demand
- Best for new attorneys
Related Courses
CMS Nationwide Moratoria on New Hospice and Home Health Medicare Enrollments: Covered Entities, Industry Impact
Wednesday, July 8, 2026
1:00 PM ET/10:00 AM PT
Structuring Indemnification Provisions in Business Associate Agreements: Allocating Risk in Healthcare Contracting
Tuesday, September 1, 2026
1:00 PM ET/10:00 AM PT
Healthcare M&A and State Mini-HSR Laws: Navigating an Evolving Patchwork of State Antitrust Obligations
Wednesday, July 29, 2026
1:00 PM ET/10:00 AM PT
AI in Mental Healthcare: New State Laws Impacting the Use of AI and Companion Chatbots in Patient Care
Tuesday, July 21, 2026
1:00 PM ET/10:00 AM PT
Recommended Resources
Navigating Modern Legal Challenges: A Comprehensive Guide
- Business & Professional Skills
- Career Advancement